Purdue Pharma L.P. Receives FDA Approval for Butrans (buprenorphine) Transdermal System CIII

Purdue Pharma L.P. Receives FDA Approval for Butrans (buprenorphine) Transdermal System CIII
Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration approved Butrans⢠Transdermal System CIII for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time.  Butrans Transdermal System is an analgesic product that delivers continuous release of medication for seven days.
Read more on PR Newswire via Yahoo! Finance

Mental health professionals offer help to Gulf residents
It has been two months since the Deepwater Horizon incident, but the rippling effects are now being felt closer to home. In a way to help with the stress and other matters involved with the oil spill the mental health professionals of Lakeview…
Read more on Santa Rosa Press Gazette